CompletedNot Applicable

A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia

United Kingdom103 participantsStarted 2016-12

Plain-language summary

Severe community acquired pneumonia is common and associated with high mortality. Conventional microbiological diagnostics identify pathogens in approximately half of cases, which is inadequate for both clinical and epidemiological purposes. This study applies next-generation sequencing based metagenomic techniques to patients with extremely severe community acquired pneumonia, to investigate the microbiome of severe community acquired pneumonia and evaluate metagenomic approaches as diagnostic tools.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 or over * Admitted to a participating severe respiratory failure centre or ICU * Admitted due to community acquired pneumonia (CAP) according to clinical and radiological criteria * Tracheal intubation, receiving mechanical ventilation +/- ECMO * Requires bronchoscopy as part of routine diagnostic care plan * Bronchoscopy takes place within 72 hours of first admission to hospital Exclusion Criteria: * Any current or previous condition/circumstance that, in the opinion of the investigator or study nurse, may put the individual at risk if participating * Patients receiving end of life care * Hospitalisation within the previous 28 days (not including pre-ECMO hospitalisation for ECMO patients) * Consent or assent not given

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Detection of pathogens by metagenomic sequencing applied to bronchoalveolar lavage samples

Timeframe: 28 days (From time of enrollment up until end of inclusion)

Trial details

NCT IDNCT02963142

SponsorImperial College London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-10

View on ClinicalTrials.gov More Community Acquired Pneumonia trials